227 related articles for article (PubMed ID: 30544140)
1. Multiple Cytokine Profiling: A New Model to Predict Response to Tumor Necrosis Factor Antagonists in Ulcerative Colitis Patients.
Obraztsov IV; Shirokikh KE; Obraztsova OI; Shapina MV; Wang MH; Khalif IL
Inflamm Bowel Dis; 2019 Feb; 25(3):524-531. PubMed ID: 30544140
[TBL] [Abstract][Full Text] [Related]
2. Targeted
Notararigo S; Martín-Pastor M; Viñuela-Roldán JE; Quiroga A; Dominguez-Munoz JE; Barreiro-de Acosta M
J Mol Med (Berl); 2021 Sep; 99(9):1251-1264. PubMed ID: 34021361
[TBL] [Abstract][Full Text] [Related]
3. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis.
Hassan EA; Ramadan HK; Ismael AA; Mohamed KF; El-Attar MM; Alhelali I
Saudi J Gastroenterol; 2017; 23(4):238-245. PubMed ID: 28721978
[TBL] [Abstract][Full Text] [Related]
5. Normalization of mucosal tumor necrosis factor-α: A new criterion for discontinuing infliximab therapy in ulcerative colitis.
Olsen T; Rismo R; Gundersen MD; Paulssen EJ; Johnsen K; Kvamme JM; Goll R; Florholmen J
Cytokine; 2016 Mar; 79():90-5. PubMed ID: 26775117
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-6 is associated with steroid resistance and reflects disease activity in severe pediatric ulcerative colitis.
Wine E; Mack DR; Hyams J; Otley AR; Markowitz J; Crandall WV; Leleiko N; Muise AM; Griffiths AM; Turner D
J Crohns Colitis; 2013 Dec; 7(11):916-22. PubMed ID: 23339932
[TBL] [Abstract][Full Text] [Related]
7. Serum interleukin-6 level is associated with response to infliximab in ulcerative colitis.
Nishida Y; Hosomi S; Watanabe K; Watanabe K; Yukawa T; Otani K; Nagami Y; Tanaka F; Taira K; Kamata N; Yamagami H; Tanigawa T; Watanabe T; Fujiwara Y
Scand J Gastroenterol; 2018 May; 53(5):579-585. PubMed ID: 29171305
[TBL] [Abstract][Full Text] [Related]
8. Global mucosal and serum cytokine profile in patients with ulcerative colitis undergoing anti-TNF therapy.
Dahlén R; Magnusson MK; Bajor A; Lasson A; Ung KA; Strid H; Öhman L
Scand J Gastroenterol; 2015; 50(9):1118-26. PubMed ID: 25877762
[TBL] [Abstract][Full Text] [Related]
9. Role of serum cytokine profile in ulcerative colitis assessment.
Rodríguez-Perálvarez ML; García-Sánchez V; Villar-Pastor CM; González R; Iglesias-Flores E; Muntane J; Gómez-Camacho F
Inflamm Bowel Dis; 2012 Oct; 18(10):1864-71. PubMed ID: 22238172
[TBL] [Abstract][Full Text] [Related]
10. Quantitative gene expression of cytokines in peripheral blood leukocytes stimulated in vitro: modulation by the anti-tumor nerosis factor-alpha antibody infliximab and comparison with the mucosal cytokine expression in patients with ulcerative colitis.
Moriconi F; Raddatz D; Ho NA; Yeruva S; Dudas J; Ramadori G
Transl Res; 2007 Oct; 150(4):223-32. PubMed ID: 17900510
[TBL] [Abstract][Full Text] [Related]
11. Compassionate access anti-tumour necrosis factor-α therapy for ulcerative colitis in Australia: the benefits to patients.
Costello SP; Ghaly S; Beswick L; Pudipeddi A; Agarwal A; Sechi A; O'Connor S; Connor SJ; Sparrow MP; Bampton P; Walsh AJ; Andrews JM;
Intern Med J; 2015 Jun; 45(6):659-66. PubMed ID: 25732268
[TBL] [Abstract][Full Text] [Related]
12. Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy.
Baird AC; Mallon D; Radford-Smith G; Boyer J; Piche T; Prescott SL; Lawrance IC; Tulic MK
World J Gastroenterol; 2016 Nov; 22(41):9104-9116. PubMed ID: 27895398
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis.
Su C; Salzberg BA; Lewis JD; Deren JJ; Kornbluth A; Katzka DA; Stein RB; Adler DR; Lichtenstein GR
Am J Gastroenterol; 2002 Oct; 97(10):2577-84. PubMed ID: 12385442
[TBL] [Abstract][Full Text] [Related]
14. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
[TBL] [Abstract][Full Text] [Related]
15. Changes in cytokine profile may predict therapeutic efficacy of infliximab in patients with ulcerative colitis.
Sato S; Chiba T; Nakamura S; Matsumoto T
J Gastroenterol Hepatol; 2015 Oct; 30(10):1467-72. PubMed ID: 25968585
[TBL] [Abstract][Full Text] [Related]
16. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis.
Rismo R; Olsen T; Cui G; Christiansen I; Florholmen J; Goll R
Scand J Gastroenterol; 2012 May; 47(5):538-47. PubMed ID: 22486187
[TBL] [Abstract][Full Text] [Related]
17. Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis.
Brandse JF; van den Brink GR; Wildenberg ME; van der Kleij D; Rispens T; Jansen JM; Mathôt RA; Ponsioen CY; Löwenberg M; D'Haens GR
Gastroenterology; 2015 Aug; 149(2):350-5.e2. PubMed ID: 25917786
[TBL] [Abstract][Full Text] [Related]
18. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.
Lawson MM; Thomas AG; Akobeng AK
Cochrane Database Syst Rev; 2006 Jul; (3):CD005112. PubMed ID: 16856078
[TBL] [Abstract][Full Text] [Related]
19. Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease.
Billiet T; Cleynen I; Ballet V; Claes K; Princen F; Singh S; Ferrante M; Van Assche G; Gils A; Vermeire S
Scand J Gastroenterol; 2017 Oct; 52(10):1086-1092. PubMed ID: 28622097
[TBL] [Abstract][Full Text] [Related]
20. Cultured blood T-cell responses predict anti-TNF therapy response in patients with ulcerative colitis.
Magnusson MK; Strid H; Isaksson S; Bajor A; Lasson A; Ung KA; Öhman L
Aliment Pharmacol Ther; 2015 Jun; 41(11):1149-61. PubMed ID: 25858346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
